BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
0.1112
-0.0057 (-4.8760%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.1169
Open0.1200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1112 - 0.1200
52 Week Range0.1060 - 0.8970
Volume2,710,956
Avg. Volume2,084,007
Market Cap13.894M
Beta0.21
PE Ratio (TTM)N/A
EPS (TTM)-0.2580
Earnings DateSep 13, 2017 - Sep 15, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.80
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    BioPharmX Reports Third Quarter 2018 Financial Results

    MENLO PARK, Calif. , Dec. 7, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focusing on dermatology, today announces its financial results for the ...

  • PR Newswire8 days ago

    BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-inflammatory Properties for the Treatment of Acne at ASCB 2017

    MENLO PARK, Calif., Dec. 4, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share research suggesting that BPX-01, the company's topical gel formulation of minocycline, may exhibit relevant antimicrobial and anti-inflammatory properties for the treatment of acne. Data from cellular analysis shows minocycline's effectiveness may be due to its antimicrobial effect and its ability to modulate the effects of pro-inflammatory cytokines associated with acne pathology.

  • Capital Cube11 days ago

    ETFs with exposure to BioPharmX Corp. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioPharmX Corp. Here are 5 ETFs with the largest exposure to BPMX-US. Comparing the performance and risk of BioPharmX Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire21 days ago

    BioPharmX Corporation Announces Pricing of Public Offering

    MENLO PARK, Calif. , Nov. 21, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE AMERICAN: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the pricing ...

  • GlobeNewswire26 days ago

    Report: Developing Opportunities within Graphic Packaging Holding, Invitation Home, Teradyne, Dean Foods, Valley National, and BioPharmX — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 16, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Graphic ...

  • Should You Be Concerned About BioPharmX Corporation’s (BPMX) Shareholders?
    Simply Wall St.28 days ago

    Should You Be Concerned About BioPharmX Corporation’s (BPMX) Shareholders?

    In this analysis, my focus will be on developing a perspective on BioPharmX Corporation’s (AMEX:BPMX) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • PR Newswirelast month

    BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans

    MENLO PARK, Calif., Nov. 8, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announces it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding design of its planned phase 3 clinical trial for BPX-011, the company's topical minocycline gel for the treatment of inflammatory lesions of acne vulgaris. The company has incorporated feedback from the FDA on key elements of its phase 3 acne program and received clear guidance regarding expectations and requirements for clinical, non-clinical, and chemistry, manufacturing and controls (CMC) needed to support a post phase 3 NDA submission.

  • Capital Cubelast month

    ETFs with exposure to BioPharmX Corp. : November 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioPharmX Corp. Here are 5 ETFs with the largest exposure to BPMX-US. Comparing the performance and risk of BioPharmX Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire2 months ago

    BioPharmX to Present at Re-entering Antibacterial Discovery and Development Summit 2017

    MENLO PARK, Calif., Oct. 18, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX) will share research suggesting that BPX-01, the company's topical gel formulation of minocycline, may be useful in the treatment of inflammatory skin diseases, including acne and papulopustular rosacea, particularly as the medical community has growing concerns about antibiotic resistance secondary to systemic exposure. A presentation at the Re-entering Antibacterial Discovery and Development Summit on Oct. 18-20 in Boston concludes that minocycline is effective in fighting gram-positive and gram-negative bacteria, as well as other micro-organisms implicated in rosacea and acne – while also alleviating the inflammation they cause.

  • PR Newswire2 months ago

    BioPharmX Collaborates with Wellman Center for Photomedicine to Develop Pioneering, Cost-Effective Technique to Visualize Drug Delivery

    MENLO PARK, Calif., Oct. 11, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX) researchers were part of a national scientific team that developed an innovative way to use nonlinear optical imaging to confirm the efficiency and quantity of the delivery of new drugs. A presentation at the 2017 Fall Clinical Dermatology Conference will show how researchers from BioPharmX and the Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School used a suite of imaging techniques in what is called "Pharmacokinetic Tomography" to confirm highly localized delivery of BPX-01, BioPharmX's unique topical, hydrophilic gel formulation of minocycline for the treatment of acne vulgaris, to the area of the skin where acne develops.

  • Is BioPharmX Corporation (BPMX) Still A Cheap Healthcare Stock?
    Simply Wall St.2 months ago

    Is BioPharmX Corporation (BPMX) Still A Cheap Healthcare Stock?

    BioPharmX Corporation (AMEX:BPMX), a USD$26.38M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronicRead More...

  • Capital Cube3 months ago

    ETFs with exposure to BioPharmX Corp. : September 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioPharmX Corp. Here are 5 ETFs with the largest exposure to BPMX-US. Comparing the performance and risk of BioPharmX Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • ACCESSWIRE3 months ago

    Earnings Review and Free Research Report: Can-Fite’s Revenue Increased 25%

    Research Desk Line-up: BioPharmX Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 25, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Can-Fite BioPharma Ltd (NYSE: ...

  • Capital Cube3 months ago

    ETFs with exposure to BioPharmX Corp. : September 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioPharmX Corp. Here are 5 ETFs with the largest exposure to BPMX-US. Comparing the performance and risk of BioPharmX Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • BioPharmX Corp. :BPMX-US: Earnings Analysis: Q2, 2018 By the Numbers : September 14, 2017
    Capital Cube3 months ago

    BioPharmX Corp. :BPMX-US: Earnings Analysis: Q2, 2018 By the Numbers : September 14, 2017

    Categories: Yahoo FinanceGet free summary analysis BioPharmX Corp. reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of BioPharmX Corp. – Supernus Pharmaceuticals, Inc., Foamix Pharmaceuticals Ltd., Achaogen, Inc. and Zogenix, Inc. (SUPN-US, FOMX-US, AKAO-US and ZGNX-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)

  • PR Newswire3 months ago

    BioPharmX Reports Second Quarter 2018 Financial Results

    Company reports continued progress in clinical programs MENLO PARK, Calif. , Sept. 13, 2017 /PRNewswire/ --   BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, ...

  • PR Newswire3 months ago

    BioPharmX Announces Preliminary Data from Rosacea Feasibility Study

    MENLO PARK, Calif., Sept. 12, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, is announcing preliminary data from a feasibility study of BPX-01 to assess the safety and efficacy of topical minocycline gel at both the 1% and 2% doses for the treatment of rosacea.  The preliminary data from the ongoing study suggest good tolerability and promising efficacy of BPX-01 in this indication and highlight the value of BioPharmX's dermatology delivery system.

  • PR Newswire3 months ago

    BioPharmX to Present at Rodman & Renshaw 19th Annual Global Investment Conference

    MENLO PARK, Calif. , Sept. 5, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that Anja Krammer ...

  • PR Newswire5 months ago

    Summer AAD Panel to Discuss BPX-01 for Acne and Rosacea

    MENLO PARK, Calif. , July 27, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that a panel ...

  • PR Newswire5 months ago

    BioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017

    MENLO PARK, Calif., July 13, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, will present results of its phase 2b research of BPX-01, a unique topical hydrophilic gel formulation of minocycline, at the Dermatology Education Foundation's Essential Resource Meeting, DERM 2017, being held July 20-23 in Las Vegas. The study also found BPX-01 was generally well tolerated, without any serious drug-related adverse events experienced, photosensitivity, staining or skin discoloration.

  • Capital Cube5 months ago

    ETFs with exposure to BioPharmX Corp. : July 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioPharmX Corp. Here are 5 ETFs with the largest exposure to BPMX-US. Comparing the performance and risk of BioPharmX Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Accesswire6 months ago

    Corporate News Blog - Repligen Corp. and Spectrum Merge to Form Leader in Filtration for Bioprocessing Industry

    Research Desk Line-up: BioPharmX Corporation Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...

  • PR Newswire6 months ago

    BioPharmX to Present Phase 2b Clinical Trial Acne Data at Alabama Dermatology Society Summer Symposium

    MENLO PARK, Calif., June 22, 2017 /PRNewswire/-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, will present results of its phase 2b of BPX-01, a unique topical hydrophilic gel formulation of minocycline, at the Alabama Dermatology Society's Summer Symposium being held June 22-25 in Sandestin, Fla. Findings from the phase 2b will be discussed during the presentation "Acne Vulgaris: What Do Available and Newer Therapies Bring to the Table?"  by Dr. James Q. Del Rosso, founder of JDR Dermatology Research, Las Vegas.

  • Capital Cube6 months ago

    ETFs with exposure to BioPharmX Corp. : June 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioPharmX Corp. Here are 5 ETFs with the largest exposure to BPMX-US. Comparing the performance and risk of BioPharmX Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • BioPharmX Corp. :BPMX-US: Earnings Analysis: Q1, 2018 By the Numbers : June 16, 2017
    Capital Cube6 months ago

    BioPharmX Corp. :BPMX-US: Earnings Analysis: Q1, 2018 By the Numbers : June 16, 2017

    Categories: Yahoo FinanceGet free summary analysis BioPharmX Corp. reports financial results for the quarter ended April 30, 2017. We analyze the earnings along side the following peers of BioPharmX Corp. – Supernus Pharmaceuticals, Inc., Achaogen, Inc. and Zogenix, Inc. (SUPN-US, AKAO-US and ZGNX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.02 ... Read more (Read more...)